Gainers

• iSpecimen (NASDAQ:ISPC) shares moved upwards by 14.1% to $0.32 during Thursday's after-market session. The market value of their outstanding shares is at $3.0 million.
• BioAtla (NASDAQ:BCAB) shares increased by 6.51% to $0.17. The company's market cap stands at $10.4 million.
• Nakamoto (NASDAQ:NAKA) shares moved upwards by 3.94% to $0.26. The company's market cap stands at $170.5 million.
• Crescent Biopharma (NASDAQ:CBIO) shares moved upwards by 3.58% to $12.15. The market value of their outstanding shares is at $295.9 million.
• Candel Therapeutics (NASDAQ:CADL) stock rose 3.52% to $6.16. The company's market cap stands at $321.1 million.
• iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 3.5% to $0.4. The market value of their outstanding shares is at $6.7 million.

Losers

• GRAIL (NASDAQ:GRAL) stock fell 23.6% to $77.54 during Thursday's after-market session. The market value of their outstanding shares is at $3.9 billion. As per the press release, Q4 earnings came out today.
• Ardelyx (NASDAQ:ARDX) stock fell 16.92% to $5.6. The company's market cap stands at $1.6 billion. As per the press release, Q4 earnings came out today.
• PTC Therapeutics (NASDAQ:PTCT) stock declined by 10.28% to $62.72. The market value of their outstanding shares is at $5.5 billion. As per the news, the Q4 earnings report came out today.
• Travere Therapeutics (NASDAQ:TVTX) shares fell 7.17% to $27.2. The market value of their outstanding shares is at $2.4 billion. As per the news, the Q4 earnings report came out today.
• Profusa (NASDAQ:PFSA) shares fell 4.15% to $1.62. The company's market cap stands at $2.1 million.
• Theriva Biologics (AMEX:TOVX) stock declined by 4.1% to $0.21. The company's market cap stands at $6.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.